Myriad Genetics
MYGN
MYGN
235 hedge funds and large institutions have $2.14B invested in Myriad Genetics in 2019 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 92 increasing their positions, 75 reducing their positions, and 45 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less call options, than puts
Call options by funds: $ | Put options by funds: $
18% less capital invested
Capital invested by funds: $2.62B → $2.14B (-$477M)
51% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 45
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
Holders
235
Holding in Top 10
–
Calls
$21.2M
Puts
$25.7M
Top Buyers
| 1 | +$28.8M | |
| 2 | +$18.3M | |
| 3 | +$14.1M | |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.99M |
| 5 |
Morgan Stanley
New York
|
+$9.84M |
Top Sellers
| 1 | -$110M | |
| 2 | -$15.8M | |
| 3 | -$14.5M | |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$7.97M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.96M |